Compare McKesson Corporation (MCK) vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? McKesson Corporation trades at $832.45 (market cap $97.35B), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $63.5. The key difference: McKesson Corporation pays a 0.39% dividend while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 pays none, and McKesson Corporation is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals.
| MCK | SLVO | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $995.69 | $107.41 |
52-Week Low | $659.01 | $61.81 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
SLVO trades at $62.98, up 0.99% today, but technical indicators show a bearish trend with all 13 moving average signals recommending sell. The stock faces resistance at $63-$64 with support at $61-$62. Fundamental data appears incomplete in the current snapshot, requiring verification of financial metrics.
The technical setup suggests near-term pressure with strong bearish momentum indicators. Investment appeal depends on verification of underlying financial performance and business fundamentals, which are currently unavailable in the provided data. Risk remains elevated given the technical deterioration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →
